Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer

Table 1 Clinical characteristics of patients in the treatment and control groups

Clinical features	LS-SCLC		P value	ES-SCLC		P value	All patients		P value
Clinical features	Control	Study	P value	Control	Study	P value	Control	Study	P value
Sex
Male	14	11	0.438	7	11	0.155	21	22	1.000
Female	3	6	0.438	5	1	0.155	8	7	1.000
Age, years
Median	61	61	0.898	58.5	62.5	0.045	60	62	0.215
Range	43–80	41–77	0.898	46–67	54–79	0.045	43–80	41–79	0.215
Smoking index
Median	400	300	0.572	600	600	0.861	500	400	0.716
Range	0–1350	0–2000	0.572	0–1200	0–1200	0.861	0–1350	0–2000	0.716
ECOG
≤1	14	15	1.000	12	10	0.478	26	25	1.000
2	3	2	1.000	0	2	0.478	3	4	1.000
Chemotherapy courses
Median	6	5	0.141	6	6	1.000	6	6	0.187
Range	4–6	4–6	0.141	4–6	4–6		4–6	4–6	0.187
Radiotherapy
Yes	17	17	1.000	6	8	0.680	23	25	0.730
No	0	0	1.000	6	4		6	4	0.730
Surgery
Yes	2	2	1.000	0	2	0.478	2	4	0.666
No	15	15	1.000	12	10	0.478	27	25	0.666
Chemotherapy responses *
CR	7	5	0.822	1	2	1.000	8	7	1.000
PR	7	8		7	6		14	14
SD	3	4		4	4		7	8

Abbreviations: ECOG, Eastern Cooperative Oncology Group; CR, complete remission; PR, partial remission; SD, stable disease; LS-SCLC, limited stage small cell lung cancer; ES-SCLC, extensive stage small cell lung cancer
Note: *The responses for the first-line therapy

ISSN: 1479-5876